ES2514140B1 - Uso del inhibidor de sulfatasas esteroideas STX64 para el tratamiento del envejecimiento - Google Patents
Uso del inhibidor de sulfatasas esteroideas STX64 para el tratamiento del envejecimiento Download PDFInfo
- Publication number
- ES2514140B1 ES2514140B1 ES201330436A ES201330436A ES2514140B1 ES 2514140 B1 ES2514140 B1 ES 2514140B1 ES 201330436 A ES201330436 A ES 201330436A ES 201330436 A ES201330436 A ES 201330436A ES 2514140 B1 ES2514140 B1 ES 2514140B1
- Authority
- ES
- Spain
- Prior art keywords
- stx64
- aging
- treatment
- steroid sulfatase
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/91—Injection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/92—Oral administration
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Uso del inhibidor de sulfatasas esteroideas STX64 para el tratamiento del envejecimiento.#La presente invención se refiere al uso del inhibidor de la actividad de la enzima sulfatasa esteroidea STX64 para el tratamiento del envejecimiento y, por tanto, para incrementar la longevidad de los individuos o mejorar la calidad de vida de éstos. También se refiere a una composición cosmética que comprenda dicho inhibidor con ese fin.
Description
Claims (1)
-
imagen1
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES201330436A ES2514140B1 (es) | 2013-03-26 | 2013-03-26 | Uso del inhibidor de sulfatasas esteroideas STX64 para el tratamiento del envejecimiento |
PCT/ES2014/070230 WO2014154927A1 (es) | 2013-03-26 | 2014-03-26 | Uso del inhibidor de sulfatasas esteroideas stx64 para el tratamiento del envejecimiento |
EP14775264.6A EP3011950A4 (en) | 2013-03-26 | 2014-03-26 | Use of the inhibitor of steroid sulfatases stx64 for treating aging |
US14/907,658 US20160361244A1 (en) | 2013-03-26 | 2014-03-26 | Use of the inhibitor of steroid sulfatases stx64 for treating aging |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES201330436A ES2514140B1 (es) | 2013-03-26 | 2013-03-26 | Uso del inhibidor de sulfatasas esteroideas STX64 para el tratamiento del envejecimiento |
Publications (2)
Publication Number | Publication Date |
---|---|
ES2514140A1 ES2514140A1 (es) | 2014-10-27 |
ES2514140B1 true ES2514140B1 (es) | 2015-08-03 |
Family
ID=51622473
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES201330436A Active ES2514140B1 (es) | 2013-03-26 | 2013-03-26 | Uso del inhibidor de sulfatasas esteroideas STX64 para el tratamiento del envejecimiento |
Country Status (4)
Country | Link |
---|---|
US (1) | US20160361244A1 (es) |
EP (1) | EP3011950A4 (es) |
ES (1) | ES2514140B1 (es) |
WO (1) | WO2014154927A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4098264A1 (en) * | 2017-06-01 | 2022-12-07 | Nexyon Biotech Co., Ltd. | Pharmaceutical composition for prevention or treatment of bone-related disease |
US20210251953A1 (en) * | 2018-06-19 | 2021-08-19 | Universidad Pablo De Olavide | Compositions for treating and/or preventing protein-aggregation diseases |
KR102162633B1 (ko) | 2019-03-13 | 2020-10-07 | 연세대학교 산학협력단 | 비만 또는 지질 관련 대사성 질환의 예방 또는 치료용 조성물 |
EP3988095A1 (en) * | 2020-10-26 | 2022-04-27 | Universidad Pablo de Olavide | Sulfated c19 steroid hormones to extend lifespan and protect against aging-associated proteotoxicity |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995026717A1 (en) | 1994-04-05 | 1995-10-12 | Celltech Therapeutics Limited | Use of estrone derivatives as steroid sulphatase inhibitors |
US5556847A (en) * | 1994-10-27 | 1996-09-17 | Duquesne University Of The Holy Ghost | Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors |
JP4320089B2 (ja) | 1999-07-06 | 2009-08-26 | あすか製薬株式会社 | フェニルスルファメート誘導体 |
GB0020498D0 (en) * | 2000-08-18 | 2000-10-11 | Sterix Ltd | Compound |
JPWO2004035089A1 (ja) | 2002-10-09 | 2006-02-09 | 協和醗酵工業株式会社 | ホルモン依存性癌の治療剤 |
US8030298B2 (en) * | 2005-05-26 | 2011-10-04 | Abbott Products Gmbh | 17β-HSD1 and STS inhibitors |
GB0511190D0 (en) * | 2005-06-01 | 2005-07-06 | Sterix Ltd | Use |
GB0624105D0 (en) * | 2006-12-01 | 2007-01-10 | Sterix Ltd | Use |
CA2684604A1 (en) * | 2007-05-15 | 2008-11-27 | Puretech Ventures | Methods and compositions for treating skin conditions |
AU2010236016A1 (en) * | 2010-02-01 | 2011-08-18 | Peter Maccallum Cancer Institute | Method of treatment of EGFR inhibitor toxicity |
-
2013
- 2013-03-26 ES ES201330436A patent/ES2514140B1/es active Active
-
2014
- 2014-03-26 EP EP14775264.6A patent/EP3011950A4/en not_active Withdrawn
- 2014-03-26 WO PCT/ES2014/070230 patent/WO2014154927A1/es active Application Filing
- 2014-03-26 US US14/907,658 patent/US20160361244A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2014154927A1 (es) | 2014-10-02 |
ES2514140A1 (es) | 2014-10-27 |
US20160361244A1 (en) | 2016-12-15 |
EP3011950A4 (en) | 2017-03-15 |
EP3011950A1 (en) | 2016-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2019000180A (es) | INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS | |
CL2016002027A1 (es) | Ciclopropilamina como inhibidor de la lsd1 | |
CL2017002066A1 (es) | Proteasas de cisteína | |
SV2017005461A (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
DOP2015000234A (es) | COMPOSICIONES DE ARNi CONTRA EL COMPONENTE C5 DEL COMPLEMENTO Y METODOS PARA SU USO. | |
DOP2016000109A (es) | Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas. | |
CL2016001547A1 (es) | Composiciones para el cuidado oral | |
CL2015002472A1 (es) | Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4. | |
ECSP15026557A (es) | Compuestos y sus métodos de empleo | |
CL2015002501A1 (es) | Compuestos y usos de estos para la modulación de la hemoglobina | |
AR090465A1 (es) | Formas solidas de un profarmaco de nucleotidos de tiofosforamidato | |
UY34988A (es) | Anticuerpos humanos para gfr alfa 3 y métodos para su uso | |
UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
CL2019002733A1 (es) | Formulaciones de clorhidrato del ácido 1-amino-1-ciclopropanocarboxílico. | |
ES2514140B1 (es) | Uso del inhibidor de sulfatasas esteroideas STX64 para el tratamiento del envejecimiento | |
CL2016001546A1 (es) | Composición para el cuidado oral que comprende serina y al menos una sal de zinc. | |
CO2018012180A2 (es) | Métodos de tratamiento para enfermedades colestásicas y fibróticas | |
DOP2018000066A (es) | Compuestos útiles para inhibir ror-gamma-t | |
CL2017000845A1 (es) | Inhibidores de gingipaina de lisina | |
CL2016002151A1 (es) | Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico | |
BR112017009000A2 (pt) | apilimod para uso no tratamento de melanoma | |
PE20150167A1 (es) | (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel | |
CL2015000537A1 (es) | Siarn y su uso en los métodos y composiciones para el tratamiento y/o prevención de enfermedades de los ojos. | |
CL2017000563A1 (es) | Uso de elsiglutida para tratar mucositis gastrointestinal que incluye diarrea inducida por quimioterapia. | |
CL2015002191A1 (es) | Composición antifúngica tópica para el tratamiento de onicomicosis. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 2514140 Country of ref document: ES Kind code of ref document: B1 Effective date: 20150803 |